Cigna Corporation

(New York Stock Exchange)
Back to all articles
Somewhat Bullish +45

[CI] Cigna: Q3 2026 Earnings Test Whether Pharmacy Benefit Profit Has ...

Company update Earnings report AI-generated analysis

πŸ“ˆ Cigna reported Q2 2026 adjusted EPS of $7.78 (+8%) with total revenue rising 7% to $71.668 billion.

πŸ“‰ Pharmacy Benefit Services profit fell 27% in Q2 due to client renewal concessions and transition spending on the Signature model.

πŸš€ Cigna Healthcare profit surged 17% to $1.276 billion, driven by strong employer business performance.

πŸ’° Management reaffirmed full-year adjusted EPS guidance of at least $30.45 and revenue of about $280 billion.

πŸ”„ The company sold its Medicare Advantage business for $4.9 billion in March 2025 to Health Care Service Corporation.

πŸ‘” Brian Evanko succeeded David Cordani as CEO on July 1, 2026, with Cordani moving to executive chair.

πŸ₯ Cigna Healthcare's Medical Care Ratio was 84.5% in Q2, up from 79.8% in Q1 due to seasonal factors.

πŸ’Š Specialty and Care Services profit grew 21% in the first half, offsetting declines in pharmacy benefits.

πŸ“… Cigna is scheduled to report Q3 2026 earnings on November 5, 2026, with consensus EPS of $7.545.

πŸ›‘οΈ The company introduced a 'Lead to One' strategy and plans $3 billion in modernization initiatives at its investor day.

πŸ“‰ Q1 and Q2 Pharmacy Benefit Services profits declined 28% and 27% respectively due to regulatory pressure and client concessions.

πŸ₯ Cigna Healthcare serves 3.701 million fully insured members and 14.712 million ASO members as of June 30, 2026.

πŸ’Έ First-half operating cash flow was $710 million, with full-year targets dependent on second-half collections.

πŸ“‰ The company repurchased 11.9 million shares for about $3.6 billion in 2025 and maintains a debt-to-capitalization ratio of 42.8%.

Bullish Signals
  • Cigna Healthcare profit grew 17% to $1.276 billion in Q2, demonstrating strong performance in the self-funded employer segment.
  • Specialty and Care Services profit increased 21% in the first half of 2026, successfully offsetting declines in pharmacy benefits.
  • Management raised full-year adjusted EPS guidance to at least $30.45 and reaffirmed revenue guidance of about $280 billion.
  • Cigna Healthcare's Medical Care Ratio improved to 84.5% in Q2, indicating better cost management compared to the prior quarter.
  • The company successfully sold its Medicare Advantage business for $4.9 billion, reducing exposure to government program risk.
Risk Factors
  • Pharmacy Benefit Services profit declined 27% in Q2 due to client renewal concessions and spending on the rebate-free Signature model.
  • Claim volume in the pharmacy segment fell 2% sequentially in Q2, adding pressure to profitability margins.
  • The company faces regulatory headwinds from new legislation requiring 100% rebate pass-throughs starting in August 2028.
  • First-half operating cash flow was only $710 million, significantly impacted by timing of accounts receivable factoring settlements.
Full Analysis
Cigna Group (NYSE: CI) reported Q2 2026 results with adjusted EPS of $7.78, marking an 8% increase year-over-year despite a 27% decline in Pharmacy Benefit Services profit. The company is now preparing to report Q3 2026 earnings on November 5, 2026, which will be critical for determining if the pharmacy benefit profit decline has bottomed out as specialty growth momentum slows. Management reaffirmed its full-year adjusted EPS guidance of at least $30.45 and total revenue of approximately $280 billion during a September investor day. The company's business mix continues to shift, with Cigna Healthcare showing strong 17% profit growth while the pharmacy segment faces headwinds from client renewal concessions and spending on its rebate-free Signature model. Three key metrics will define Q3 performance: whether Pharmacy Benefit Services profit stabilizes after significant declines, if Specialty and Care Services can sustain rapid growth following biosimilar switching peaks, and if Cigna Healthcare's Medical Care Ratio remains stable. The company has raised its full-year EPS outlook to at least $30.45, implying a minimum of $14.87 in the second half. Cigna is executing a strategic transformation involving the sale of its Medicare Advantage business for $4.9 billion and an upcoming exit from Individual and Family Plans in 2027. Leadership changes include Brian Evanko succeeding David Cordani as CEO, alongside a new 'Lead to One' direction focused on modernization initiatives totaling $3 billion over multiple years.